Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
E-mail:
Password:
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


3B PLAYER by 3B NEXUS

Close [ X ]
Copy this code to embed & stream this video on your website
 
Copy this URL to share or create a link back to this video
Dr. Klaus Giese
Chief Scientific Officer
Germany
Pre-Clinical and Clinical Development of Atu027, a Liposomal siRNA, for Therapy in Oncology
Atu027, a novel RNAi therapeutic composed of liposomally formulated siRNA, is currently being tested in a Phase I clinical trial in oncology. This investigational drug targets the expression of PKN3 in the vascular endothelium and shows inhibition of tumor growth and strong anti-metastatic activity in various pre-clinical models. Latest developments on Atu027 will be discussed.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
00:00
, Silence Therapeutics: Delivering on the Promise of RNAi Therapeutics
00:11
, Silence Today
01:12
, Outstanding potential of RNAi therapeutics
02:47
, AtuRNAi: Best-in-class siRNA therapeutics platform
03:46
, Breakthrough delivery technologies
04:20
, Silence's DACC delivery system is highly specific targeting the lung
04:41
, Silence's DBTC delivery system is highly specific to liver
05:10
, Strong validation through partnerships
05:42
, Industry's broadest siRNA therapeutics clinical pipeline
06:29
, Atu027 targeting PKN3 for RNAi mediated cancer therapy
07:32
, Atu027: Strong preclinical efficacy data
08:43
, Clinical Phase-I trial with Atu027
09:21
, Atu027 Phase I summary and outlook
10:26
, Delivering on the Promise of RNAi Therapeutics